• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24828 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after expiry: diffuse large B-cell lymphoma)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tisagenlecleucel (Reassessment after Expiry: B-cell Acute Lymphoblastic Leukaemia)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tisagenlecleucel (new therapeutic indication: follicular lymphoma, pretreated patients)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tebentafusp (uveal melanoma, HLA-A*02:01-positive)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Talquetamab (multiple myeloma, at least 3 prior therapies)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tagraxofusp (blastic plasmacytoid dendritic cell neoplasm, first-line)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tafasitamab (diffuse large B-cell lymphoma (DLBCL), combination with lenalidomide)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tabelecleucel (Epstein-Barr virus positive post-transplantation lymphoproliferative disease)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Sutimlimab (cold agglutinin disease)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Sutimlimab (cold agglutinin disease)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Somatrogon (growth disturbance due to growth hormone deficiency, ≥ 3 to < 18 years]
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Sirolimus (facial angiofibroma associated with tuberous sclerosis complex, ≥ 6 years)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Setmelanotide (obesity and control of hunger, POMC, PCSK1 or LEPR-deficiency obesity, ≥ 6 years)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Setmelanotide (new therapeutic indication: obesity and control of hunger, Bardet-Biedl syndrome, ≥ 6 years)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Selumetinib (reassessment after the deadline: neurofibromatosis (≥ 3 to < 18 years, type 1))]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Selumetinib (neurofibromatosis (≥ 3 to < 18 years, type 1))]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Sebelipase alfa (reassessment after expiry of the deadline (lysosomal acid lipase deficiency))]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Satralizumab (neuromyelitis optica spectrum disorders, anti-aquaporin-4IgG seropositive, ≥ 12 years)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ripretinib (gastrointestinal stromal tumours (GIST), ≥ 3 prior therapies)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ponatinib (Reassessment after the Deadline: Chronic Myeloid Leukaemia)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ponatinib (Reassessment after the Deadline: Acute Lymphoblastic Leukaemia)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (new therapeutic indication: diffuse large B-cell lymphoma (DLBCL), combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP))]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (Diffuse Large B-Cell Lymphoma, Combination with Bendamustine and Rituximab)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Pitolisant (new therapeutic indication: narcolepsy, with or without cataplexy, (children and adolescents, 6 - 17 years))]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Pemigatinib (cholangiocarcinoma with FGFR2 fusion or FGFR2 rearrangement, after at least one prior therapy)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Pegvaliase]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Pegcetacoplan (paroxysmal nocturnal haemoglobinuria, pretreated patients)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Osilodrostat (Endogenous Cushing’s Syndrome)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Olipudase Alfa (acid sphingomyelinase deficiency (ASMD) type A/B or B)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Odevixibat (progressive familial intrahepatic cholestasis)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Mosunetuzumab (follicular lymphoma, after ≥ 2 prior therapies)]
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Momelotinib (myelofibrosis)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Mogamulizumab (Mycosis Fungoides, Sézary Syndrome)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Migalastat (new therapeutic indication: Fabry disease, 12 to < 16 years)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Mexiletine]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Maribavir (cytomegalovirus infection (refractory to therapies))]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Maribavir (cytomegalovirus infection (refractory to therapies))]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Maralixibat (Alagille syndrome, ≥ 2 months)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Maralixibat (Alagille syndrome, ≥ 2 months)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Luspatercept (β-thalassaemia)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Luspatercept (Myelodysplastic Syndrome (MDS))]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Lumasiran (Hyperoxaluria)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Lonapegsomatropin (growth failure due to growth hormone deficiency, ≥ 3 to < 18 years)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Lonafarnib (Hutchinson-Gilford progeria syndrome or progeroid laminopathy, 12 months and older)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ixazomib]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ixazomib (reassessment after the deadline: multiple myeloma, at least 1 prior therapy, combination with lenalidomide and dexamethasone)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ivosidenib (cholangiocarcinoma with IDH1 R132 mutation, after at least 1 prior therapy)]
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ivosidenib (acute myeloid leukaemia with IDH1 R132 mutation, first-line, combination with azacitidine)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (exceeding the € 50 million limit, cystic fibrosis, combination treatment with Ivacaftor in patients 12 years and older (homozygous for F508del mutation))]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (Exceeding the € 50 Million Limit, Cystic Fibrosis, Combination Treatment with Ivacaftor in Patients 12 Years and Older (Heterozygous for F508del and MF Mutation))]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Imlifidase (desensitisation in kidney transplantation)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Idecabtagen vicleucel (multiple myeloma, at least 3 prior therapies)]
2016     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Idebenone]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Idebenone (reassessment after the deadline: Leber's Hereditary Optic Neuropathy)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glycerol phenylbutyrate (New Therapeutic Indication: Urea cycle disorders in infants aged 0 to < 2 months)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glucarpidase (reduction of toxic plasma methotrexate concentrations; aged 28 days and older)]
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glofitamab (diffuse large B-cell lymphoma, after ≥ 2 prior therapies)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glasdegib (acute myeloid leukaemia (AML), combination with cytarabine (LDAC))]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Gilteritinib (Relapsed or Refractory Acute Myeloid Leukaemia with an FLT3 Mutation)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Fenfluramine (new therapeutic indication: Lennox-Gastaut syndrome, add-on therapy, ≥ 2 years)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Fedratinib (myelofibrosis)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Etranacogene dezaparvovec (haemophilia B)]
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Epcoritamab (diffuse large B-cell lymphoma, after ≥ 2 prior therapies)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Eladocagene exuparvovec (Aromatic-L-amino acid decarboxylase (AADC) deficiency, ≥ 18 months)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Efgartigimod alfa (Myasthenia Gravis, AChR-antibody+)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Delamanid (repeal of the exemption: pulmonary multi-drug resistant tuberculosis, ≥ 10 kg)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Crizanlizumab (repeal of the resolution of 20 May 2021)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ciltacabtagene autoleucel (relapsing/ refractory multiple myeloma, after at least 3 prior therapies)]
2017     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Cerliponase Alfa]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Cerliponase Alfa - reassessment after the deadline (type 2 neuronal ceroid lipofuscinosis)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Caplacizumab (New Therapeutic Indication: Acquired Thrombotic Thrombocytopenic Purpura, 12 to < 18 Years)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Cannabidiol (New Therapeutic Indication: seizures associated with tuberous sclerosis, ≥ 2 years, adjunctive therapy)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Lennox-Gastaut-Syndrome, ≥ 2 years, combination with clobazam)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Dravet-Syndrome, ≥ 2 years, combination with clobazam)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Cabozantinib (reassessment after the deadline: thyroid carcinoma)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bulevirtide (chronic hepatitis delta virus (HDV) infection)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Brexucabtagene Autoleucel (new therapeutic indication: relapsed or refractory B-cell precursor acute lymphoblastic leukaemia, 26 years of age and above)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Brentuximab Vedotin (reassessment after the deadline: systemic anaplastic large cell lymphoma; first-line; combination with Cyclophosphamide, Doxorubicin, and Prednisone)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Blinatumomab (new therapeutic indication: acute lymphoblastic B-cell leukaemia, high-risk first relapse, Ph-, CD19+, ≥1 and <18 years)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Blinatumomab (new therapeutic indication: acute lymphatic leukaemia, paediatric patients aged 1 year or older)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Blinatumomab (new therapeutic indication: acute lymphatic leukaemia, MRD-positive patients)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Birch Bark Extract (treatment of wounds associated with epidermolysis bullosa (6 months and older))]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Betibeglogene autotemcel (β-thalassaemia) (treatment costs)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Benefit assessment of medicinal products with new active ingredients according to section 35a SGB V: Blinatumomab (new therapeutic indication: B-precursor acute lymphoblastic leukaemia, relapsed or refractory, Ph+ CD19+)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Belantamab mafodotin (reassessment after the deadline: multiple myeloma, at least 4 prior therapies, monotherapy)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Belantamab mafodotin (multiple myeloma, at least 4 prior therapies, monotherapy)]
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bedaquiline (reassessment after the deadline: pulmonary multidrug-resistant tuberculosis)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bedaquiline (new therapeutic indication: pulmonary multidrug-resistant tuberculosis, 5 to 11 years)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bedaquiline (new therapeutic indication: multi-drug-resistant pulmonary tuberculosis, 12 to < 18 years)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bedaquiline (assessment of an orphan drug after exceeding the turnover limit of €1 million)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Axicabtagene ciloleucel]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Axicabtagene Ciloleucel (reassessment after the deadline: (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Axicabtagene ciloleucel (PMBCL)]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: systemic mastocytosis, after at least 1 prior therapy)]
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: indolent systemic mastocytosis (ISM))]